These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31055958)

  • 1. The FOsmetpantotenate Replacement Therapy (FORT) randomized, double-blind, Placebo-controlled pivotal trial: Study design and development methodology of a novel primary efficacy outcome in patients with pantothenate kinase-associated neurodegeneration.
    Klopstock T; Escolar ML; Marshall RD; Perez-Dueñas B; Tuller S; Videnovic A; Greblikas F
    Clin Trials; 2019 Aug; 16(4):410-418. PubMed ID: 31055958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration.
    Klopstock T; Videnovic A; Bischoff AT; Bonnet C; Cif L; Comella C; Correa-Vela M; Escolar ML; Fraser JL; Gonzalez V; Hermanowicz N; Jech R; Jinnah HA; Kmiec T; Lang A; Martí MJ; Mercimek-Andrews S; Monduy M; Nimmo GAM; Perez-Dueñas B; Pfeiffer HCV; Planellas L; Roze E; Thakur N; Tochen L; Vanegas-Arroyave N; Zorzi G; Burns C; Greblikas F
    Mov Disord; 2021 Jun; 36(6):1342-1352. PubMed ID: 33200489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: Mechanism of action and efficacy in nonclinical models.
    Elbaum D; Beconi MG; Monteagudo E; Di Marco A; Quinton MS; Lyons KA; Vaino A; Harper S
    PLoS One; 2018; 13(3):e0192028. PubMed ID: 29522513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.
    Klopstock T; Tricta F; Neumayr L; Karin I; Zorzi G; Fradette C; Kmieć T; Büchner B; Steele HE; Horvath R; Chinnery PF; Basu A; Küpper C; Neuhofer C; Kálmán B; Dušek P; Yapici Z; Wilson I; Zhao F; Zibordi F; Nardocci N; Aguilar C; Hayflick SJ; Spino M; Blamire AM; Hogarth P; Vichinsky E
    Lancet Neurol; 2019 Jul; 18(7):631-642. PubMed ID: 31202468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational Design of Novel Therapies for Pantothenate Kinase-Associated Neurodegeneration.
    Thakur N; Klopstock T; Jackowski S; Kuscer E; Tricta F; Videnovic A; Jinnah HA
    Mov Disord; 2021 Sep; 36(9):2005-2016. PubMed ID: 34002881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Scale to Assess Activities of Daily Living in Pantothenate Kinase-Associated Neurodegeneration.
    Marshall RD; Collins A; Escolar ML; Jinnah HA; Klopstock T; Kruer MC; Videnovic A; Robichaux-Viehoever A; Swett L; Revicki DA; Bender RH; Lenderking WR
    Mov Disord Clin Pract; 2019 Feb; 6(2):139-149. PubMed ID: 30838313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical rating scale for pantothenate kinase-associated neurodegeneration: A pilot study.
    Darling A; Tello C; Martí MJ; Garrido C; Aguilera-Albesa S; Tomás Vila M; Gastón I; Madruga M; González Gutiérrez L; Ramos Lizana J; Pujol M; Gavilán Iglesias T; Tustin K; Lin JP; Zorzi G; Nardocci N; Martorell L; Lorenzo Sanz G; Gutiérrez F; García PJ; Vela L; Hernández Lahoz C; Ortigoza Escobar JD; Martí Sánchez L; Moreira F; Coelho M; Correia Guedes L; Castro Caldas A; Ferreira J; Pires P; Costa C; Rego P; Magalhães M; Stamelou M; Cuadras Pallejà D; Rodríguez-Blazquez C; Martínez-Martín P; Lupo V; Stefanis L; Pons R; Espinós C; Temudo T; Pérez Dueñas B
    Mov Disord; 2017 Nov; 32(11):1620-1630. PubMed ID: 28845923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.
    Iankova V; Karin I; Klopstock T; Schneider SA
    Front Neurol; 2021; 12():629414. PubMed ID: 33935938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic Phosphopantothenic Acid Prodrugs for Treatment of Pantothenate Kinase-Associated Neurodegeneration.
    Auciello G; Di Marco A; Gonzalez Paz O; Malancona S; Harper S; Beconi M; Rossetti I; Ciammaichella A; Fezzardi P; Vecchi A; Bracacel E; Cicero D; Monteagudo E; Elbaum D
    J Med Chem; 2020 Dec; 63(24):15785-15801. PubMed ID: 33320012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial.
    Harvey PD; Bowie CR; McDonald S; Podhorna J
    Clin Drug Investig; 2020 Apr; 40(4):377-385. PubMed ID: 32036587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-Label Fosmetpantotenate, a Phosphopantothenate Replacement Therapy in a Single Patient with Atypical PKAN.
    Christou YP; Tanteles GA; Kkolou E; Ormiston A; Konstantopoulos K; Beconi M; Marshall RD; Plotkin H; Kleopa KA
    Case Rep Neurol Med; 2017; 2017():3247034. PubMed ID: 28567317
    [No Abstract]   [Full Text] [Related]  

  • 19. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep brain stimulation for pantothenate kinase-associated neurodegeneration: A meta-analysis.
    De Vloo P; Lee DJ; Dallapiazza RF; Rohani M; Fasano A; Munhoz RP; Ibrahim GM; Hodaie M; Lozano AM; Kalia SK
    Mov Disord; 2019 Feb; 34(2):264-273. PubMed ID: 30633810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.